miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer

L Du, Z Zhao, X Ma, TH Hsiao, Y Chen, E Young… - Oncogene, 2014 - nature.com
L Du, Z Zhao, X Ma, TH Hsiao, Y Chen, E Young, M Suraokar, I Wistuba, JD Minna
Oncogene, 2014nature.com
Abstract The disabled homolog 2 (DAB2) gene was recently identified as a tumor
suppressor gene with its expression downregulated in multiple cancer types. The role of
DAB2 in lung tumorigenesis, however, is not fully characterized, and the mechanisms of
DAB2 dysregulation in lung cancer are not defined. Here we show that low DAB2 levels in
lung tumor specimens are significantly correlated with poor patient survival, and that DAB2
overexpression significantly inhibits cell growth in cultured lung cancer cells, indicating its …
Abstract
The disabled homolog 2 (DAB2) gene was recently identified as a tumor suppressor gene with its expression downregulated in multiple cancer types. The role of DAB2 in lung tumorigenesis, however, is not fully characterized, and the mechanisms of DAB2 dysregulation in lung cancer are not defined. Here we show that low DAB2 levels in lung tumor specimens are significantly correlated with poor patient survival, and that DAB2 overexpression significantly inhibits cell growth in cultured lung cancer cells, indicating its potent tumor suppressor function. We next identify that microRNA miR-93 functions as a potent repressor of DAB2 expression by directly targeting the 3′ UTR of the DAB2 mRNA. Using in vitro and in vivo approaches, we demonstrate that miR-93 overexpression has an important role in promoting lung cancer cell growth, and that its oncogenic function is primarily mediated by downregulating DAB2 expression. Our clinical investigations further indicate that high tumor levels of miR-93 are correlated with poor survival of lung cancer patients. The correlations of both low DAB2 and high miR-93 expression levels with poor patient survival strongly support the critical role of the miR-93/DAB2 pathway in determining lung cancer progression.
nature.com